Skip to main content

Blog

Welcome to The Happy Lungs Project Blog. We seek to support researchers and clinicians in their work toward a cure for Non-Small Cell Lung Cancer caused by the RET mutation. We also aim to provide community resources and events to support finding a cure for RET Positive Lung Cancer. On this blog, you will find information about our research, RET clinical trials, patient stories and upcoming events. Thanks for stopping by.

Filter

together separately live stream

3/13/24 Live Virtual Meetup About IASLC Targeted Therapies

#TogetherSeparately: live virtual meetup to summarize data presented on February’s IASLC Targeted Therapies Meeting. March 13 at 3PM…
March 11, 2024
elipses pharma ep0031

Ellipses’ RET inhibitor EP0031/A400 Granted Fast Track Designation by FDA

Ellipses’ next generation selective RET inhibitor EP0031/A400 granted Fast Track designation by FDA Ellipses Pharma…
March 11, 2024
harmonic never smoker lung cancer trial

The Harmonic™ Clinical Trial for Never Smokers

New clinical trial for never smokers: The Harmonic™ clinical trial The Harmonic™ clinical trial is…
March 9, 2024
oncogene testing RET lung cancer

Looking Ahead: The Future of Diagnostic Testing for Patients

By: Anthony Sireci, M.D., senior vice president, clinical biomarkers and diagnostics development, Loxo@Lilly Over the…
January 7, 2024
ret cancer research 2023

2023 RET Cancer Research Update

2023 Happy Lungs Project RET research update On Friday December 8th, the Happy Lungs Project…
December 18, 2023
RET lung cancer study 2023

Exciting Preclinical Results About Vepafestinib

New published study with exciting preclinical results about the second generation RET inhibitor vepafestinib (TAS0953/HM06).  Vepafestinib showed selectivity…
October 10, 2023
lung cancer research

New clinical trial testing amivantamab

New clinical trial testing amivantamab for patients who progressed on RET therapies:  A Phase 1…
October 8, 2023
biomarker testing RET cancer

Finding the Right Time to Ask About Biomarker Testing

By: Anthony Sireci, M.D., senior vice president, clinical biomarkers and diagnostics development, Loxo@Lilly Increasingly, cancer…
July 27, 2023
on and off target ret resistance

Two research studies funded by HLP were presented at 2023 ASCO annual meeting

Last week was the 2023 American Society of Clinical Oncology (ASCO) conference in Chicago. The…
June 19, 2023

Ellipses Pharma presents ‘encouraging’ data on selective RET inhibitor EP0031, ASCO 2023 annual conference

Data of the Phase 1 Study of KL590586 (EP0031/A400), presented at ASCO, reported preliminary efficacy…
June 19, 2023

DAVA’s 2nd Hawaii Global Summit on Thoracic Malignancies

The DAVA’s 2nd Hawaii Global Summit on Thoracic Malignancies is a five-day meeting comprising seven…
June 19, 2023
cancer medical care team

Understanding the Role of a Care Team in Treatment Planning

By: Anthony Sireci, M.D., senior vice president, clinical biomarkers and diagnostics development, Loxo@Lilly When someone…
April 18, 2023
happy lungs project logo
We are a 501(c)(3) non-profit, patient-driven community. Our mission is to support researchers and clinicians in their work towards finding a cure for RET-Positive Non-Small Cell Lung Cancer, while educating and empowering patients in their own healing journey.

Email: info@happylungsproject.org

Phone: 512-337-9352

Address: 3209 Sunny Ln. Austin, TX 78731

ABOUT
RESOURCES
GET INVOLVED
RESEARCH

© 2024 Happy Lungs Project | Privacy Policy | Terms of Service | Designed by Reinhardt Designs